Queen’s Partnerships and Innovation invites Researchers, Faculty & Staff to join us on May 24 at 10:15 am to hear BioCanRx President speak about the network’s commercialization, training programs for immunotherapy researchers and programs that address knowledge and skills gaps in clinical translational research. Learn about the status of Car-T and other immunotherapies research and innovation communities in Canada as well as insights on the future of opportunities in this sector.

About BioCanRx

BioCanRx is Canada’s Immunotherapy Network. The BioCanRx vision is to turn all cancers into curable diseases. We invest in leading edge immune oncology research translating world-class technologies from the lab into early phase clinical trials. BioCanRx provides researchers with access to funding, expertise, training and biomanufacturing facilities and is a leader in the translation, manufacture and adoption of cancer immunotherapies.

About Stéphanie Michaud

Dr. Stéphanie Michaud is the President and CEO of BioCanRx and is responsible for running all facets of the organization. She brings more than 20 years of public, government and private sector experience in research and Science & Technology innovation policy. She strives to create partnerships between government, not-for-profits, academia and industry to maximize the impact of research funded by the BioCanRx network on the lives of those affected by cancer.